Canaccord Genuity Group Inc. (CF.TO) Research
Canaccord Genuity Group Inc. functions as a diversified financial services enterprise, delivering a broad spectrum of investment products, along with specialized investment banking and brokerage solutions, to a diverse clientele including institutional entities, corporations, and private individuals. The firm organizes its activities into two primary divisions: Canaccord Genuity Capital Markets and Canaccord Genuity Wealth Management. The Capital Markets segment specializes in corporate advisory, in-depth research, mergers and acquisitions, sales, trading, and investment banking activities. Conversely, the Wealth Management arm offers comprehensive wealth management strategies, brokerage services, and financial planning tailored for individual investors, high-net-worth clients, charitable organizations, and financial intermediaries. With operations spanning North America, the United Kingdom, Europe, Asia, Australia, and the Middle East, the company boasts a significant global footprint. Canaccord Genuity Group Inc. was established in 1950, with its corporate headquarters situated in Vancouver, Canada.
Market snapshot
- Symbol
- CF.TO
- Price
- $14.78
- Day change
- -0.81%
- Market cap
- $1.5B
- P/E ratio
- -10.19x
- 52-week range
- 9.01-15.12
- Sector
- Financial Services
- Industry
- Financial - Capital Markets
- Next earnings
- in 2 months
Recent news
- St George Mining secures A$60 million to fast-track rare earths-niobium project in Brazil
St George Mining Ltd (ASX:SGQ, FRA:S0G, OTC:SGQMF) has secured firm commitments to raise A$60 million, strengthening its balance sheet as it advances the...
- US approved DeepSeek for its trade blacklist, then sat on it for eight months
An interagency committee approved DeepSeek, CXMT and more than 100 other Chinese firms for the Entity List last year. Commerce never published the names....
Peer companies
Open Canaccord Genuity Group Inc. (CF.TO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.